TrialNet
Staff at the Bristol coordinating centre
Type 1 Diabetes TrialNet is an international network of leading academic institutions, physicians, scientists and healthcare teams throughout the United States, Canada, Denmark, Sweden, Finland, United Kingdom (UK), Italy, Germany, Australia and New Zealand, dedicated to the prevention of type 1 diabetes (T1D).
To learn more about the TrialNet programme, visit the international TrialNet website at www.trialnet.org.
In the UK, TrialNet comprises the Clinical Centre in Bristol and affiliate sites throughout the UK, listed below. Prof. Polly Bingley, at the University of Bristol is the UK Chief Investigator.
- Aberdeen
- Belfast
- Birmingham
- Blackburn
- Brighton
- Cambridge
- Cardiff
- Exeter
- Glasgow
- Harrogate
- Hull
- Leeds
- Leicester
- Liverpool
- London
- Manchester
- Newcastle
- Norwich
- Nottingham
- Ormskirk
- Plymouth
- Sheffield
- Taunton
There are currently three TrialNet studies open in the UK.
1. The TrialNet Pathway to Prevention (PTP) study is an observational study in which relatives of people with T1D are screened to assess their risk of developing T1D. This study is helping us to understand more about the Natural History of T1D and learn more about how diabetes occurs. Through this screening study it is possible to identify those individuals who are at greater risk of developing T1D and who are therefore potentially eligible to take part in TrialNet T1D prevention studies. There are two phases to the PTP study:
Screening Phase
Participants (aged 3-45 years) have a simple blood test to look for 3 to 5 diabetes-related autoantibodies. If a participant has one or more autoantibodies they will be offered further follow-up in the Monitoring phase. If no autoantibodies are present and they are under the age of 18 years they will be invited to come back for re-screening every year. If the participant is over 18 years, no more participation in the study is required. Find out more https://www.trialnet.org/our-research/risk-screening.
Monitoring Phase
All participants who are found to have one or more autoantibodies in the screening phase are offered the monitoring phase of the study. Participants have an oral glucose tolerance test and further antibody and genetic testing. Follow up tests will then be carried out every 6 or 12 months depending on their level of risk. Find out more https://www.trialnet.org/our-research/monitoring.
2. The Abatacept Study for the Prevention of T1D opened in the UK in 2014. Abatacept is a drug that is used in rheumatoid arthritis and other autoimmune conditions. We are testing to see if it can delay or prevent progression of early stage T1D and ultimately prevent clinical diagnosis. Find out more https://www.trialnet.org/our-research/prevention-studies/abatacept.
3. The Long-Term Investigative Follow-Up in TrialNet (LIFT) Study is for participants who have been diagnosed with T1D whilst participating in one of our other TrialNet studies. It is helping us to understand what is happening in the stages of T1D. Find out more https://www.trialnet.org/our-research/long-term-follow-up.
Participate
If you are interested in taking part in the Pathway to Prevention study, please complete our online form which helps us to determine your eligibility and we will contact you to discuss the study further.
Contact the team
If you would like to find out more about TrialNet in the UK, please contact the team at the Bristol Clinical Centre.
Diabetes and Metabolism
Translational Health Sciences
Bristol Medical School
University of Bristol
Learning & Research
Southmead Hospital
Bristol
BS10 5NB
Telephone: 0117 414 7920
Email: trialnet-uk@bristol.ac.uk